Literature DB >> 22946905

The relationship between mental health diagnosis and treatment with second-generation antipsychotics over time: a national study of U.S. Medicaid-enrolled children.

Meredith Matone1, Russell Localio, Yuan-Shung Huang, Susan dosReis, Chris Feudtner, David Rubin.   

Abstract

OBJECTIVE: To describe the relationship between mental health diagnosis and treatment with antipsychotics among U.S. Medicaid-enrolled children over time. DATA SOURCES/STUDY
SETTING: Medicaid Analytic Extract (MAX) files for 50 states and the District of Columbia from 2002 to 2007. STUDY
DESIGN: Repeated cross-sectional design. Using logistic regression, outcomes of mental health diagnosis and filled prescriptions for antipsychotics were standardized across demographic and service use characteristics and reported as probabilities across age groups over time. DATA COLLECTION: Center for Medicaid Services data extracted by means of age, ICD-9 codes, service use intensity, and National Drug Classification codes. PRINCIPAL
FINDINGS: Antipsychotic use increased by 62 percent, reaching 354,000 youth by 2007 (2.4 percent). Although youth with bipolar disorder, schizophrenia, and autism proportionally were more likely to receive antipsychotics, youth with attention deficit hyperactivity disorder (ADHD) and those with three or more mental health diagnoses were the largest consumers of antipsychotics over time; by 2007, youth with ADHD accounted for 50 percent of total antipsychotic use; 1 in 7 antipsychotic users were youth with ADHD as their only diagnosis.
CONCLUSIONS: In the context of safety concerns, disproportionate antipsychotic use among youth with nonapproved indications illustrates the need for more generalized efficacy data in pediatric populations. © Health Research and Educational Trust.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22946905      PMCID: PMC3513608          DOI: 10.1111/j.1475-6773.2012.01461.x

Source DB:  PubMed          Journal:  Health Serv Res        ISSN: 0017-9124            Impact factor:   3.402


  26 in total

1.  Predictive margins with survey data.

Authors:  B I Graubard; E L Korn
Journal:  Biometrics       Date:  1999-06       Impact factor: 2.571

2.  Psychotropic practice patterns for youth: a 10-year perspective.

Authors:  Julie Magno Zito; Daniel J Safer; Susan DosReis; James F Gardner; Laurence Magder; Karen Soeken; Myde Boles; Frances Lynch; Mark A Riddle
Journal:  Arch Pediatr Adolesc Med       Date:  2003-01

3.  Effect of Medicaid eligibility category on racial disparities in the use of psychotropic medications among youths.

Authors:  Julie Magno Zito; Daniel J Safer; Ilene H Zuckerman; James F Gardner; Karen Soeken
Journal:  Psychiatr Serv       Date:  2005-02       Impact factor: 3.084

4.  Trends in the use of typical and atypical antipsychotics in children and adolescents.

Authors:  Nick C Patel; M Lynn Crismon; Kimberly Hoagwood; Michael T Johnsrud; Karen L Rascati; James P Wilson; Peter S Jensen
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2005-06       Impact factor: 8.829

Review 5.  Risperidone in the management of agitation and aggression associated with psychiatric disorders.

Authors:  Peter Paul De Deyn; Jan Buitelaar
Journal:  Eur Psychiatry       Date:  2006-01-18       Impact factor: 5.361

6.  National trends in the use of outpatient psychotherapy.

Authors:  Mark Olfson; Steven C Marcus; Benjamin Druss; Harold Alan Pincus
Journal:  Am J Psychiatry       Date:  2002-11       Impact factor: 18.112

7.  Trends in the prescribing of psychotropic medications to preschoolers.

Authors:  J M Zito; D J Safer; S dosReis; J F Gardner; M Boles; F Lynch
Journal:  JAMA       Date:  2000-02-23       Impact factor: 56.272

Review 8.  Safety of low doses of quetiapine when used for insomnia.

Authors:  Holly V Coe; Irene S Hong
Journal:  Ann Pharmacother       Date:  2012-04-17       Impact factor: 3.154

9.  Risperidone for the treatment of affective symptoms in children with disruptive behavior disorder: a post hoc analysis of data from a 6-week, multicenter, randomized, double-blind, parallel-arm study.

Authors:  Joseph Biederman; Eric Mick; Stephen V Faraone; Janet Wozniak; Thomas Spencer; Gahan Pandina
Journal:  Clin Ther       Date:  2006-05       Impact factor: 3.393

10.  Current prescribing patterns in outpatient child and adolescent psychiatric practice in central New York.

Authors:  Jud A Staller; Michael J Wade; Molly Baker
Journal:  J Child Adolesc Psychopharmacol       Date:  2005-02       Impact factor: 2.576

View more
  30 in total

1.  Head-to-Head Comparison of Aripiprazole and Risperidone in the Treatment of ADHD Symptoms in Children with Autistic Spectrum Disorder and ADHD: A Pilot, Open-Label, Randomized Controlled Study.

Authors:  Marco Lamberti; Rosamaria Siracusano; Domenico Italiano; Norma Alosi; Francesca Cucinotta; Gabriella Di Rosa; Eva Germanò; Edoardo Spina; Antonella Gagliano
Journal:  Paediatr Drugs       Date:  2016-08       Impact factor: 3.022

2.  Introducing the Best of the AcademyHealth Annual Research Meeting.

Authors:  José J Escarce; Jacqueline S Zinn
Journal:  Health Serv Res       Date:  2012-10       Impact factor: 3.402

3.  Second-Generation Antipsychotic Utilization and Metabolic Parameter Monitoring in an Inpatient Pediatric Population: A Retrospective Analysis.

Authors:  Valerie D Nolt; Alexandra Victoria Kibler; G Lucy Wilkening; Tanya J Fabian
Journal:  Paediatr Drugs       Date:  2017-04       Impact factor: 3.022

4.  The effects of prior authorization policies on medicaid-enrolled children's use of antipsychotic medications: evidence from two mid-Atlantic states.

Authors:  Bradley D Stein; Emily Leckman-Westin; Edward Okeke; Deborah M Scharf; Mark Sorbero; Qingxian Chen; Ka Ho Brian Chor; Molly Finnerty; Jennifer P Wisdom
Journal:  J Child Adolesc Psychopharmacol       Date:  2014-08-21       Impact factor: 2.576

5.  Effectiveness of mandatory peer review to reduce antipsychotic prescriptions for Medicaid-insured children.

Authors:  Ayse Akincigil; Thomas I Mackie; Sharon Cook; Robert J Hilt; Stephen Crystal
Journal:  Health Serv Res       Date:  2020-06-21       Impact factor: 3.402

Review 6.  Antipsychotic and psychostimulant drug combination therapy in attention deficit/hyperactivity and disruptive behavior disorders: a systematic review of efficacy and tolerability.

Authors:  David Linton; Alasdair M Barr; William G Honer; Ric M Procyshyn
Journal:  Curr Psychiatry Rep       Date:  2013-05       Impact factor: 5.285

7.  Antipsychotic polypharmacy in children and adolescents at discharge from psychiatric hospitalization.

Authors:  Shannon N Saldaña; Brooks R Keeshin; Anna M Wehry; Thomas J Blom; Michael T Sorter; Melissa P DelBello; Jeffrey R Strawn
Journal:  Pharmacotherapy       Date:  2014-07-03       Impact factor: 4.705

8.  Age at Exposure to Surgery and Anesthesia in Children and Association With Mental Disorder Diagnosis.

Authors:  Caleb Ing; Ming Sun; Mark Olfson; Charles J DiMaggio; Lena S Sun; Melanie M Wall; Guohua Li
Journal:  Anesth Analg       Date:  2017-12       Impact factor: 5.108

9.  Antipsychotic treatment patterns and aggressive behavior among adolescents in residential facilities.

Authors:  Leslie Miller; Mark A Riddle; David Pruitt; Al Zachik; Susan dosReis
Journal:  J Behav Health Serv Res       Date:  2013-01       Impact factor: 1.505

10.  Second-generation antipsychotic use among stimulant-using children, by organization of medicaid mental health.

Authors:  Brendan Saloner; Meredith Matone; Amanda R Kreider; M Samer Budeir; Dorothy Miller; Yuan-Shung Huang; Ramesh Raghavan; Benjamin French; David Rubin
Journal:  Psychiatr Serv       Date:  2014-11-17       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.